The COX-2 Gene and the Immune System
NCT01678222 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117
Last updated 2026-05-22
Summary
Background:
\- The immune system contains several different types of cells in the blood and other parts of the body. The body can fight infections well with the right balance of these cell types. The wrong balance of cell types may cause diseases, such as allergies or asthma. The COX-2 gene may help decide the balance of cell types that the body makes as part of the immune system. It may also play a role in certain immune system diseases. Researchers want to see how COX-2 affects the cells in the immune system.
Objectives:
\- To study how the COX-2 gene works in the body s immune system.
Eligibility:
\- Individuals 18 years of age and above who are part of the Environmental Polymorphisms Registry.
Design:
* Participants will have one study visit at the National Institutes of Health. They will collect a urine sample at home on the morning of the study visit.
* Participants will have a physical exam and medical history. They will provide a blood sample. They will also give researchers the urine sample they collected that morning.
* No treatment will be provided as part of this study.
Conditions
- Allergic Inflammation
- Asthma
Sponsors & Collaborators
-
National Institute of Environmental Health Sciences (NIEHS)
lead NIH
Principal Investigators
-
Darryl C Zeldin, M.D. · National Institute of Environmental Health Sciences (NIEHS)
Eligibility
- Min Age
- 18 Years
- Max Age
- 150 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-05-02
Countries
- United States
Study Locations
More Related Trials
-
Evaluation of Immune Signaling Networks in Healthy Human Volunteers
NCT01882582 ·Status: COMPLETED
-
Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects
NCT04408950 ·Status: COMPLETED
-
The Effects of Upper Airway and Digestive Tract Tumors on the Immune System
NCT00001603 ·Status: COMPLETED
-
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
NCT00001158 ·Status: COMPLETED
-
Social Experiences and Demographic Factors in the Regulation of Immune Cells
NCT06519487 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Effects of Systemically Administered Hydrocortisone on the Immune System in Healthy Volunteers
NCT01281995 ·Status: COMPLETED
-
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy
NCT02931955 ·Status: COMPLETED
-
Thymic Function in Patients With COVID-19
NCT04716907 ·Status: COMPLETED
-
Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment
NCT02453113 ·Status: COMPLETED ·Phase: NA
-
Angelica Gigas Dietary Supplements and Human Immune Cells
NCT03630328 ·Status: COMPLETED ·Phase: NA
-
CD8 Reactivity to Microorganisms in Blood and Breast Milk
NCT03084614 ·Status: TERMINATED
-
Collection of Data and Samples From Healthy Donors for Use in Translational Research
NCT00090662 ·Status: RECRUITING
-
Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies
NCT01915992 ·Status: UNKNOWN ·Phase: NA
-
Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection
NCT04362865 ·Status: COMPLETED
-
Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients
NCT02565589 ·Status: COMPLETED
-
An Open Label Study of IgG Fc Glycan Composition in Human Immunity
NCT01967238 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma
NCT03354390 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies
NCT04266093 ·Status: ENROLLING_BY_INVITATION
-
The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases
NCT01180868 ·Status: COMPLETED
-
Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT
NCT02452697 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics
NCT04871932 ·Status: RECRUITING
-
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy
NCT06089967 ·Status: COMPLETED
-
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
NCT01906632 ·Status: COMPLETED ·Phase: NA
-
Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients
NCT00085930 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
NCT05620342 ·Status: RECRUITING ·Phase: EARLY_PHASE1